Infinity Pharmaceuticals Inc Revenue Growth Rates (INFI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Infinity Pharmaceuticals Inc   (NASDAQ: INFI)
 

INFI's Revenue Growth by Quarter and Year

Infinity Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INFI Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.58
1st Quarter March 0.73
FY 1.31

INFIs Annual Revenue
Infinity Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 2.59 millions
Infinity Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 1.86 millions
Infinity Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 1.72 millions
Infinity Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 3.05 millions
Infinity Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 22.15 millions




INFI Revenue second quarter 2023 Y/Y Growth Comment
Infinity Pharmaceuticals Inc reported decline in Revenue in the second quarter 2023 by -15.51% to $ 0.58 millions, from the same quarter in 2022.
The contraction in the second quarter 2023 Infinity Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 11.93%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 191 other companies have achieved higher Revenue growth. While Infinity Pharmaceuticals Inc ' s Revenue fall of -15.51% ranks overall at the positon no. 3253 in the second quarter 2023.


INFI Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 20 % 2.27 % 41.94 %
3rd Quarter September - 65.12 % -14 % 47.06 %
2nd Quarter June -15.51 % 35.29 % 41.67 % 38.46 %
1st Quarter March 12.31 % 38.3 % 9.3 % -79.91 %
FY   - 39.25 % 7.51 % -

Financial Statements
Infinity Pharmaceuticals Inc 's second quarter 2023 Revenue $ 0.58 millions INFI's Income Statement
Infinity Pharmaceuticals Inc 's second quarter 2022 Revenue $ 0.69 millions Quarterly INFI's Income Statement


INFI Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -23.94 % 4.65 % -12 %
3rd Quarter September - 2.9 % -15.69 % 38.89 %
2nd Quarter June -20.14 % 6.15 % 8.51 % -16.28 %
1st Quarter March 35.19 % 44.44 % 6.82 % 38.71 %
FY (Year on Year)   - 39.25 % 7.51 % -


Back to INFI Growth rate Comparisons >> Back to INFI Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #192
Healthcare Sector #506
Overall #3253

Revenue Y/Y Growth Statistics
High Average Low
266.67 % 11.93 % -100 %
(Sep 30 2018)   (Jun 30 2017)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #192
Healthcare Sector #506
Overall #3253
Revenue Y/Y Growth Statistics
High Average Low
266.67 % 11.93 % -100 %
(Sep 30 2018)   (Jun 30 2017)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Infinity Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1759.49 % 95.52 % -100 %
(Sep 30 2015)  


INFI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Infinity Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -20.14% to $ 0.58 millions, from $ 0.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 216 other companies have achieved higher Revenue quarter on quarter growth. While Infinity Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3800.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #217
Healthcare Sector #584
Overall #3800
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #217
Healthcare Sector #584
Overall #3800
Revenue Q/Q Growth Statistics
High Average Low
1759.49 % 95.52 % -100 %
(Sep 30 2015)  


INFI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Infinity Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -20.14% to $ 0.58 millions, from $ 0.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 216 other companies have achieved higher Revenue quarter on quarter growth. While Infinity Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3800.


Infinity Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 2.57 $ 2.67 $ 2.59 $ 2.50 $ 2.22
Y / Y Revenue Growth (TTM) 15.88 % 30.79 % 39.56 % 35.78 % 16.07 %
Year on Year Revenue Growth Overall Ranking # 1216 # 870 # 1652 # 1482 # 1277
Seqeuential Revenue Change (TTM) -3.85 % 3.05 % 3.68 % 12.81 % 8.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 1762 # 1224 # 2133 # 2697 # 662


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2023 period, Infinity Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 3 millions, company would post below average annual Revenue growth of 8.52% year on year, if the fiscal year would end at Jun 30 2023.
A slow-down in the Infinity Pharmaceuticals Inc 's Revenue growth from the 0.73% growth in Mar 31 2023.

In the Healthcare sector 240 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 870 to 1216.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 241
Overall # 1216

Revenue TTM Y/Y Growth Statistics
High Average Low
1182.55 %
 88.75 %
-94.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 293
S&P 500 # 1762
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2023 period, Infinity Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 3 millions, company would post below average annual Revenue growth of -94.14% year on year, if the fiscal year would end at Jun 30 2023.
A slow-down in the Infinity Pharmaceuticals Inc 's Revenue growth from the 0.73% growth in Mar 31 2023.

In the Healthcare sector 240 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 870 to 1216.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 241
Overall # 1216

Revenue TTM Y/Y Growth Statistics
High Average Low
1182.55 %
88.75 %
-94.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 293
S&P 500 # 1762




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INFI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Fortrea Holdings Inc -0.01%$ -0.013 millions
Aquestive Therapeutics Inc -0.18%$ -0.181 millions
Phibro Animal Health Corporation-0.34%$ -0.340 millions
Procyon Corporation-0.59%$ -0.589 millions
Amedisys Inc-0.88%$ -0.882 millions
Baxter International Inc -1.04%$ -1.041 millions
Healthcare Services Group Inc -1.39%$ -1.395 millions
Bio rad Laboratories Inc -1.54%$ -1.536 millions
Harvard Bioscience Inc -1.83%$ -1.832 millions
Embecta Corp -1.92%$ -1.924 millions
Procaps Group S a -2.10%$ -2.102 millions
Enhabit Inc -2.13%$ -2.127 millions
Icu Medical Inc-2.26%$ -2.260 millions
Tandem Diabetes Care Inc -2.26%$ -2.261 millions
West Pharmaceutical Services Inc -2.27%$ -2.269 millions
Coherus Oncology inc -2.39%$ -2.386 millions
Hookipa Pharma inc -2.44%$ -2.440 millions
Biolife Solutions Inc -2.53%$ -2.529 millions
Enanta Pharmaceuticals Inc-3.01%$ -3.014 millions
Nrc Health-3.03%$ -3.033 millions
Intellia Therapeutics Inc -3.11%$ -3.108 millions
Organogenesis Holdings Inc -3.36%$ -3.365 millions
Omniab Inc -3.51%$ -3.514 millions
Marker Therapeutics inc -3.52%$ -3.523 millions
Akumin Inc -3.79%$ -3.793 millions
Endo International Plc-3.91%$ -3.912 millions
Integra Lifesciences Holdings Corp-4.16%$ -4.160 millions
Vireo Growth Inc.-4.24%$ -4.237 millions
Sonendo Inc -4.26%$ -4.257 millions
Avinger Inc -4.27%$ -4.268 millions


About Infinity Pharmaceuticals Inc Revenue Growth Rates (INFI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Infinity Pharmaceuticals Inc (CIK 1113148).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001113148-23-000009
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Infinity Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.